This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.~Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.
This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.